HDAC9 and neoplasm: Studies have shown that histone deacetylase (HDAC) makes cancer cells sensitive to ICIs therapy by up-regulating the expression of CTLA-4, PD-1, PD-L1, and PD-L2 on tumor cells and tumor infiltrating lymphocytes (TILs) (58).